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Background: Baseline values for daily step counts in US adults with COPD and knowledge of its
accurate measurement, natural change over time, and independent relationships with
measures of COPD severity are limited.
Methods: 127 persons with stable COPD wore the StepWatch Activity Monitor (SAM) for 14 days,
and 102 of them wore it a median 3.9 months later. SAM counts were compared to manual
counts in the clinic. We assessed change over time, the effect of season, and relationships with
forced expiratory volume in 1 s (FEV1) % predicted, 6-min walk test (6MWT) distance, the modi-
fied Medical Research Council (MMRC) dyspnea score, and the St. George’s Respiratory Ques-
tionnaire Total Score (SGRQ-TS).
Results: 98% of subjects were males, with mean age 71  8 years and FEV1 1.48  0.54 L
(52  19% predicted). All 4 GOLD stages were represented, with the most subjects in GOLD
II (44%) and GOLD III (37%). The SAM had >90% accuracy in 99% of subjects. Average step count
was 5680 steps/day, which decreased with increasing GOLD stage (p Z 0.0046). Subjects
walked 645 fewer steps/day at follow-up, which was partly explained by season of monitoring
(p Z 0.013). In a multivariate model, FEV1 % predicted, 6MWT distance and MMRC score were
weakly associated with daily step counts, while SGRQ-TS was not.
Conclusions: These findings will aid the design of future studies using daily step counts in
COPD. Accurately measured, daily step counts decline over time partly due to season and
capture unique information about COPD status.
Published by Elsevier Ltd.ealthcare System, Pulmonary and Critical Care Section, 1400 VFW Parkway, Mail Code 111PI, West
203 6622; fax: þ1 857 203 5670.
ov (M.L. Moy).
hed by Elsevier Ltd.
Daily step counts in COPD 963Introduction
COPD is the fourth most common cause of death in the US,
affects 5% of US adults, and accounts for a large number of
hospitalizations and unscheduled physician visits.1 A
growing body of knowledge has identified physical activity
as a modifiable factor that may impact morbidity and
mortality in COPD. Higher levels of physical activity are
associated with better functional status, fewer hospital
admissions, and lower mortality.2e4
Walking is a form of physical activity that most people can
do; it is generally a safe, convenient, and inexpensive way to
increase physical activity. Steps per day is a simple metric for
assessment of physical activity that is meaningful to persons
trying to increase their activity.5 Many studies have examined
steps per day in healthy older adults, but limited data exist for
special populations such as those with chronic illness.5 In
COPD, a higher daily step count, when directly measured, has
been associated with lower mortality in COPD, independent
of pulmonary function.6Interventions to increase daily step
counts in personswithCOPDare under development,7 andone
clinical trial studying a long-acting bronchodilator in COPD
will use daily step counts as an outcome measure.8
Although directly measured step count is an emerging
measure of health status anda target for intervention in COPD,
several methodological issues remain. First, in US adults with
COPD, baseline values for daily step counts are limited toa few
studies with a small number of participants, with no reported
values by GOLD stage.5,9 To date, daily step counts have been
reported in 10 persons with COPD in Boston, MA,4 17 persons in
Seattle, WA,10 and 21 persons in Pittsburgh, PA.11 Second,
accurate measurement of daily step counts in persons with
COPD has not been achieved.12 The majority of published
reports ondaily step counts haveused the SenseWear armband
(SenseWear, BodyMedia, Pittsburgh, USA) activity mon-
itor,6,11,13e15 which significantly underestimates step counts
when compared directly withmanual step counts.16 Third, the
magnitude of the variability in step count over time and the
impact of seasonon change in daily step counts in personswith
COPD are unclear. To date, change in physical activity over
time has been studied in COPD only in the setting of an
intervention, such as pulmonary rehabilitation.8,17e19 Finally,
the independent relationships between daily step count and
commonly used clinical measures of COPD severity, namely,
forced expiratory volume in 1 s (FEV1) % predicted, 6-min walk
test (6MWT) distance, dyspnea, and health-related quality of
life (HRQL) are unknown. Previous studies used simple corre-
lations to examine these relationships.10,11,14,15,20
In this report, we address previous limitations by (1) accu-
rately characterizing daily step counts in aUS cohort of persons
representing all GOLD stages, (2) quantifying the variability in
step count over time and season, and (3) assessing the inde-
pendent relationships between daily step count and FEV1 %
predicted, 6MWT distance, dyspnea, and HRQL.
Methods
Study population
From January 2009 through February 2011, we studied 134
persons with stable COPD defined as age over 40 years,FEV1/forced vital capacity (FVC) < 0.70 or evidence of
emphysema on chest computed tomography, and a smoking
history of >10 pack years from the pulmonary clinic at
VABoston Healthcare System. Subjects were excluded if
they were unable to ambulate. All subjects participated
when at least 4 weeks had elapsed since the most recent
COPD exacerbation. The protocol was approved by the
Committee on Human Research and informed consent was
obtained from each subject.
Clinical assessments
At the initial study visit, we assessed demographics,
smoking history, current oxygen use, prednisone use in the
previous year, and prior participation in pulmonary reha-
bilitation. Medical records were reviewed for comorbid-
ities. At initial and follow-up study visits, spirometry,
measured with an Eaglet spirometer (nSpire Health, Inc.),
and the 6MWT were performed following ATS guide-
lines.21,22 COPD severity was categorized by GOLD stage.9
Dyspnea at rest was assessed using the modified Medical
Research Council (MMRC) scale (responses 0e4 with 4 being
the most dyspneic).23 Subjects completed the St. George’s
Respiratory Questionnaire (SGRQ),24 with lower SGRQ Total
Score (SGRQ-TS) indicating better HRQL.
Step count assessments
We used the StepWatch Activity Monitor (SAM) (Orthocare
Innovations, Seattle, WA, USA), a lightweight (38 g) ankle-
worn accelerometer that accurately detects steps in
subjects with a range of physical activity levels and
mobility limitations.25 At the initial study visit, we assessed
the accuracy of the SAM by manually counting steps while
participants walked a predetermined level course of 244 m
at their usual speed.12 Bland Altman plot compared SAM
counts to manual counts in the clinic.26 We defined
acceptable device accuracy as capturing >90% of manual
counts and excluded subjects from analyses if SAM accuracy
was <90%.12
Daily step counts in the field were assessed at 2 time
points, a median of 3.9 months apart. Subjects collected
baseline step counts by wearing the SAM during waking
hours for a 14-day monitoring period, excluding periods of
bathing or other water activities. They were instructed to
perform their usual physical activities. We repeated clinical
assessments at the follow-up study visit and collected
follow-up step counts by having subjects wear the SAM for
an additional 14 days.
We defined no-use days as ones on which <200 steps
were recorded and excluded them from analyses.7 The
season during which most of the step count monitoring
occurred was recorded. The months of December, January,
February were defined as winter; March, April, May as
spring; June, July, August as summer; and September,
October, November as fall.19 We characterized the vari-
ability in baseline daily step counts with the intra-subject
and inter-subject coefficients of variation (CV).27 The CV,
a dimensionless number, is the ratio of the standard devi-
ation to the mean. The inter-subject CV reflects true
differences between participants and the intra-subject CVs
964 M.L. Moy et al.reflect day-to-day variations within each participant.27
Within subject variability of daily step counts over the
baseline 14-day monitoring period was also described by
the range (difference between the highest and lowest daily
step counts) and peak daily step count (highest daily step
count).
Statistical analysis
Of the 134 participants, there were 7 who did not complete
the initial clinic visit or baseline step count assessment as
one could not perform spirometry, one had SAM accuracy
<90%, three were unable to complete step count monitoring
during an exacerbation-free period, and two lost the SAM.
Among the 127 participants who completed the baseline step
count assessment, 19 did not return for the follow-up clinic
visit. Two died, nine did not return due to medical reasons,
six did not return due to non-medical reasons, and two were
deemed by study staff unable to complete another visit. Of
the 108 subjects who returned for follow-up, three were
unable to complete follow-up step count assessment during
an exacerbation-free period, two lost the SAM, and onewore
the SAM upside down resulting in no recorded step counts.
Therefore, data from 127 participants at baseline and 102
participants at follow-up were analyzed.
Analyses were performed with the SAS statistical soft-
ware package (9.2, SAS Institute; Cary, NC). Fisher’s Exact
Test for categorical variables and ANOVA (PROC GLM) for
continuous variables determined if characteristics differed
across GOLD stages. Average daily step count was used in
the analyses. T-tests assessed change in daily step count at
follow-up compared to baseline. The effect of season on
the change in daily step count, adjusting for baseline daily
step count, was examined (PROC GLM). The relationship
between daily step count and FEV1 % predicted, 6MWT
distance, MMRC dyspnea score, and SGRQ-TS were exam-
ined individually in univariate models and together in
a multivariate model (PROC REG and PROC GLM).
Results
Subject characteristics
Ninety-eight percent of subjects were males, with mean
age 71  8 years and FEV1 1.48  0.54 L (52  19% pre-
dicted).28 All 4 GOLD stages were represented, with the
most subjects in GOLD II (44%) and GOLD III (37%). With
increasing GOLD stage, there was a significant trend for
more subjects to report regular use of oxygen, use of
prednisone in the previous year, increasing dyspnea, and
worse SGRQ-TS (Table 1). Of 1778 total monitored days at
baseline and 1428 days at follow-up, 93 (5%) and 48 (3%),
respectively, met the definition of a no-use day.
SAM accuracy and daily step counts
In 133 of the 134 subjects (99%) who completed the initial
clinic visit, the SAM registered > 90% of the manual step
counts walked on the 244-m course. Bland Altman plot of
these data obtained in the clinic showed that the SAM, onaverage, over counted by 3 steps compared to manual
counts (Fig. 1). From the baseline step count assessments in
the field, average daily step count was 5680, with signifi-
cant trends toward lower daily step counts with increasing
GOLD stage, pZ 0.0046 (Table 2). Subjects in GOLD IV had
an average daily step count of 3707 versus 6600 in subjects
in GOLD II.
Baseline variability and short-term change in daily
step counts
117 of 127 subjects (92%) who completed the baseline step
count assessment had an intra-subject CV that was less
than the inter-subject CV of 55. There was also less within
subject variability in daily step counts, as described by the
range and peak, with increasing GOLD stage (Table 2). The
median time between the initial and follow-up clinic visits
was 3.9 months (range 3.5e8.7 months). There were no
differences in baseline average daily step count, FEV1 %
predicted, 6MWT distance, MMRC dyspnea score, or SGRQ-
TS among the 25 subjects who did not return for follow-
up compared to the 102 who returned. For the 102 partic-
ipants analyzed at follow-up, there were no significant
changes in FEV1 % predicted, 6MWT distance, MMRC dysp-
nea score, or SGRQ-TS compared to baseline (Table 3).
Daily step count was significantly lower at follow-up, with
a mean 645 fewer steps taken per day compared to base-
line. The range and peak steps per day were also signifi-
cantly lower at follow-up by 713 and 1096 steps,
respectively, compared to baseline.
Effect of season on change in daily step counts
At baseline, 14 subjects (11%) had step count monitoring in
the winter, 37 (29%) in the spring, 37 (29%) in the summer,
and 39 (31%) in the fall. Average daily step counts were
6004 (winter), 5128 (spring), 5808 (summer), and 5967
(fall). At follow-up, 35 subjects (34%) had step count
monitoring in the winter, 17 (17%) in the spring, 27 (26%) in
the summer, and 23 (23%) in the fall. Average daily step
counts were 5632 (winter), 4970 (spring), 5188 (summer),
and 4872 (fall). Although there were no significant differ-
ences in daily step counts by season at baseline or at
follow-up, there was a significant linear trend in the
magnitude of change in step count according to the season
of baseline step count monitoring, after controlling for
baseline step count (p Z 0.013). Those who had their
baseline visit in the winter and follow-up predominantly in
the spring experienced an average increase of 153 steps per
day, baseline visit in the spring and follow-up predomi-
nantly in the summer had a decline of 365 steps per day,
baseline visit in the summer and follow-up predominantly in
the fall had a decline of 770 steps per day, and baseline
visit in the fall and follow-up predominantly in the winter
had a decline of 972 steps per day.
Relationship of step counts with measures of COPD
severity
In univariate models, a higher daily step count was signif-
icantly associated with a higher FEV1 % predicted, higher
Table 1 Baseline subject characteristics.
Total GOLD I GOLD II GOLD III GOLD IV P value
N 127 7 (6) 56 (44) 47 (37) 17 (13)
Age (years) 71.4 [8.0] 71.6 [10.6] 72.8 [7.4] 70.7 [7.6] 68.5 [9.3] 0.24
BMI 28.8 [6.0] 27.9 [6.5] 29.5 [5.0] 28.5 [6.6] 28.1 [7.6] 0.73
Marital status 0.19
Married 53 (42) 3 (43) 28 (50) 14 (30) 8 (47)
Not married 74 (58) 4 (57) 28 (50) 33 (70) 9 (53)
Educational level 0.050d
Did not complete high school 22 (17) 1 (14) 11 (20) 7 (15) 3 (18)
Completed high school 30 (24) 5 (71) 7 (12) 14 (30) 4 (24)
Some college or training 57 (45) 1 (14) 29 (52) 18 (38) 9 (53)
Bachelor’s degree or higher 18 (14) 0 (0) 9(16) 8 (17) 1 (6)
Employment status 0.68
Full or part time 17 (13) 0 (0) 7 (12) 9 (19) 1 (6)
Not working 30 (24) 3 (43) 12 (21) 10 (21) 5 (29)
Retired 80 (63) 4 (57) 37 (66) 28 (60) 11 (65)
Pack years 66 [36] 69 [32] 70 [41] 61 [30] 67 [34] 0.68
Prior participation in pulmonary
rehabilitation
16 (13) 0 (0) 5 (9) 8 (17) 3 (18) 0.45
Current oxygen use 36 (28) 2 (29) 9 (16) 15 (32) 10 (59) 0.0060
Prednisone use in previous year 39 (31) 1 (14) 15 (27) 13 (28) 10 (59) 0.062
Osteoarthritis 66 (52) 4 (57) 37 (66) 19 (40) 6 (35) 0.027
Diabetes mellitus type 2 (DM) 34 (27) 3 (43) 14 (25) 12 (26) 5 (29) 0.72
Hypertension 83 (65) 3 (43) 37 (66) 31 (66) 12 (71) 0.65
Coronary artery disease (CAD) 40 (32) 3 (43) 20 (36) 12 (26) 5 (29) 0.60
FEV1 (Liters) 1.48 [0.54] 2.39 [0.47] 1.84 [0.34] 1.17 [0.21] 0.73 [0.17] <0.0001
FEV1 % predicted 51.7 [19.0] 91.0 [10.9] 64.8 [8.7] 40.0 [5.7] 24.9 [4.2] <0.0001
6MWT distance (m) 364 [102] 373 [140] 387 [96] 353 [104] 314 [84] 0.058
MMRC score 0.46d
0 5 (4) 0 (0) 4 (7) 1 (2) 0 (0.0)
1 40 (32) 2 (29) 20 (36) 14 (30) 4 (24)
2 25 (20) 1 (14) 15 (27) 7 (15) 2 (12)
3 36 (28) 2 (29) 11 (20) 17 (36) 6 (35)
4 21 (17) 2 (29) 6 (11) 8 (17) 5 (29)
SGRQ total scorea 46.4 [19.0] 48.6 [17.5] 40.5 [21.1]b 50.5 [16.3]c 53.2 [14.4] 0.019
Season of step count monitoring 0.37
Winter 14 (11) 1 (14) 8 (14) 4 (9) 1 (6)
Spring 37 (29) 1 (14) 16 (29) 11 (23) 9 (53)
Summer 37 (29) 2 (29) 13 (23) 19 (40) 3 (18)
Fall 39 (31) 3 (43) 19 (34) 13 (28) 4 (24)
Mean [standard deviation] for continuous variables and N (%) for categorical variables.
P Values for Fisher’s Exact Test (categorical variables) and ANOVA (continuous variables).
Percentages may not sum to 100 due to rounding.
a N Z 125.
b N Z 55.
c N Z 46.
d Educational level and MMRC score were dichotomized.
Daily step counts in COPD 9656MWT distance, lower MMRC score, and lower SGRQ-TS
(Table 4). Although statistically significant, FEV1 % pre-
dicted (R2 Z 0.078) and SGRQ-TS (R2 Z 0.078) explained
little of the variance in step count. Although 6MWT
distance, a measure of functional capacity like daily
step count, explained more of the variance (R2 Z 0.32),
there was a wide range of daily step counts for a given
6MWT distance (Fig. 2). In a multivariate model, FEV1 %
predicted, 6MWT distance and MMRC score weresignificantly associated with daily step counts, but SGRQ-TS
was not (Table 4).Discussion
Using a monitoring device whose accuracy was verified, our
study provides baseline values for daily step counts from
a cohort of US persons representing all GOLD stages. We
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Figure 1 BlandeAltman plot of SAM and manual counts,
n Z 127. Mean difference is 3.29 with SD of 8.58. Lower 95%
confidence limit is 13.53 and upper 95% confidence limit is
20.11.
966 M.L. Moy et al.show that short-term variability in daily step counts was
influenced by change in season. In a multivariate model,
FEV1 % predicted, 6MWT distance and MMRC score were
weakly associated with daily step counts, while SGRQ-TS
was not.
We previously reported that low walking speed and
presence of lower-limb problems predict low device accu-
racy and recommended that accuracy of devices be
confirmed in the COPD population under study.12 Other
studies have not uniformly confirmed the accuracy of
monitoring devices. To date, step counts in COPD have
been predominantly measured with the SenseWear
armband,6,11,13e15 which undercounted by an average of
486 steps when compared directly to manual counts when
persons with COPD walked a 30-m corridor.16 In contrast,
we demonstrate that step counts can be accurately
measured with the SAM, which over counted by only 3
steps. We also propose that since walking is a common
physical activity and steps per day is a simple metric that is
relevant to persons with COPD, steps per day should be the
focus of physical activity studies in COPD. Previously,
devices have reported activity units which are difficult to
understand and do not allow comparison between studies.
The RT3 accelerometer17,29 detects physical activity
movements reported in vector magnitude units (VMUs), the
Dynaport activity monitor reports time spent in walking,
cycling, standing, sitting, or lying,30 and the SenseWearTable 2 Baseline step count characteristics (mean [standard d
Total GOLD I
Average daily step count 5680 [3104] 5856 [3880]
SD of daily step count 1958 [1192] 2038 [762]
Intra-subject CV 35 [14] 40 [12]
Range of daily count 6393 [3640] 6804 [2548]
Peak daily step count 9080 [4774] 9828 [5192]armband reports total daily energy expenditure which is
then converted to a “physical activity level”.14
We demonstrate that our cohort with COPD walks
significantly less than 7000e10,000 steps per day, which is
equivalent to the minimum exercise recommendation of
30 min per day of moderate-vigorous physical activity.5 In
addition, our results suggest that the distribution of daily
step counts among persons with mild to moderate COPD is
more heterogeneous compared to those with severe COPD.
Similarly, Watz et al. studied a cohort in Germany and
reported that variability in physical activity is higher in less
severe COPD.14 These findings may have implications for
strategies to increase daily step counts in persons with
COPD. The lack of variability in daily step counts among
persons with severe COPD suggests that they are limited by
their disease and are unable to walk more even if they
wanted to. Treatment of their disease and symptoms are
needed, in addition to behavioral modifications, to further
increase their walking. In contrast, the variability seen in
daily step counts among persons with mild to moderate
COPD suggests they are capable of walking more and
behavioral strategies can be employed to maintain high
levels of walking every day.
In the absence of intervention, we found a decline in
step counts of 645 steps per day on average over the short-
term that was partly explained by season. This change was
observed in stable COPD with no change in FEV1 % pre-
dicted, 6MWT distance, MMRC dyspnea score, and SGRQ-TS
at follow-up compared to baseline. Changes in physical
activity over time have been previously studied in the
setting of an intervention. A study examining the effects of
pulmonary rehabilitation showed no change in VMUs,17 and
a study looking at the effects of a long-acting bronchodi-
lator showed no change in energy expenditure.18 Sewell
et al. previously showed that patients who started
a pulmonary rehabilitation program in the winter had
greater improvements in physical activity compared to
those who started the program in the summer.19 Our results
provide further evidence that studies of directly measured
step counts should account for expected variability and for
changes in season. Our results provide estimates for change
in step count stratified by season of baseline visit. Future
intervention studies would have control arms that can
assess seasonal changes in step counts specific to each
study.
We considered that the decrease in step count at follow-
up compared to baseline could be due to lower compliance
with wearing the SAM. We conducted a sensitivity analysis
of our compliance measure using the SAM software which
displays step counts by hour of day. We defined noncom-
pliance as a day when there were <200 steps per day ANDeviation]). P values for ANOVA.
GOLD II GOLD III GOLD IV P value
6600 [3300] 5272 [2759] 3707 [1827] 0.0046
2331 [1420] 1772 [906] 1209 [705] 0.0031
36 [16] 35 [12] 33 [9] 0.70
7445 [4182] 5913 [3018] 4087 [2312] 0.0051
10,460 [5220] 8528 [4080] 5753 [2869] 0.0026
Table 3 Clinical and step count characteristics at baseline and follow-up (N Z 102) (mean [standard deviation]).
Baseline Follow-up P value for paired
t-test for difference
FEV1 % predicted
a 51.3 [18.1] 52.4 [20.6] 0.23
6MWT distance (meters) 369 [104] 366 [108] 0.60
MMRC score 2.21 [1.19] 2.18 [1.37] 0.78
SGRQ total score 46 [19] 44 [17] 0.053
Average daily step
count (steps/day)
5878 [3267] 5233 [2822] <0.0001
SD of daily step count 1958 [1147] 1705 [1017] 0.0035
Intra-subject CV 35 [12] 34 [11] 0.38
Range of daily count 6526 [3651] 5813 [3315] 0.0072
Peak daily step count 9379 [4961] 8283 [4331] 0.0001
a N Z 101.
Daily step counts in COPD 967<8 h of wear time. For the 102 subjects, there were no
differences at baseline and follow-up in the number of
noncompliant days. Out of 1428 days of monitoring, the
total number of noncompliant days at baseline was 51
(3.6%) compared to 48 (3.4%) at follow-up. 76% of subjects
at baseline had no noncompliant days compared to 74% at
follow-up. Therefore, it is highly unlikely that the decline in
daily step counts at the second measurement time was due
to lower compliance with wearing the SAM.
Our results provide additional evidence that daily step
counts capture information not assessed by current markers
of COPD severity such as FEV1 % predicted, 6MWT distance,
dyspnea, and HRQL. Previous studies have found similar
weak to moderate relationships between walking time,
physical activity level, or daily step counts with FEV1 %
predicted, 6MWT distance, and HRQL.6,10,11,14,15,20,30
Correlation coefficients (Pearson r values) between total
steps and HRQL domains have ranged from 0.07 to 0.49.11
Waschki et al. showed correlation coefficients between
physical activity level and FEV1 % predicted and 6MWD to be
0.40 and 0.45, respectively.6 Watz et al. showed correlation
coefficients between steps per day and FEV1 % predicted
and 6MWD to be 0.46 and 0.63, respectively.14 We
hypothesized that daily step counts and HRQL would be
highly associated since they reflect both the physiological
and psychosocial status of patients. However, using
a multivariate model, we show that after adjusting for FEV1
% predicted, 6MWT distance, and MMRC score, daily step
counts and HRQL are not related. These results suggest thatTable 4 Relationship between average daily step count and me
Unadjusted
b estimateb
95% CI P v
FEV1 % predicted 45 17; 73 0
6 MW distance 17 13; 22 <0
MMRC score (ref Z 0 or 1) 2719 3757; 1681 <0
SGRQ total scorea 45 73; 18 0
a N Z 125.
b Four univariate models with average daily step count as dependen
c One multivariate model with average daily step count as dependen
Model R2 Z 0.38.daily step counts and HRQL evaluate unique constructs
related to health status in COPD.
Several limitations deserve discussion. It has been
proposed that at least 2 weeks of monitoring is needed to
capture the daily and weekly variations of physical activi-
ties.25 The intra-class correlation coefficient (ICC), the
proportion of total variance accounted for by inter-subject
sources, reflects the reliability of measurements over
multiple days.27 An ICC  0.8 is the generally accepted
value in accelerometer studies.27 We calculated a very high
ICC of 0.96 using 14 days of monitoring, and acknowledge
that 14 days may not be feasible for all studies. Since intra-
subject variation is less than inter-subject variation, our
results indicate that true differences in daily step counts
between individuals can be detected. Our cohort is
a convenience sample of predominantly men representing
a single center in the New England region of the US. The
results presented may not be generalizable to women or
persons with COPD in other regions of the US. There may
also have been selection bias of subjects who are less sick
and interested in a research study.
We did not include a control group as our primary aim
was not to compare walking in COPD to a healthy elderly
cohort. Nevertheless, the decrease in average daily step
counts with increasing GOLD stage supports a relationship
with COPD and suggests that our observations are related to
COPD and not to “normal” sedentary behavior in the Boston
area. Furthermore, the similarity between our average
daily step count of 5680 and those from smaller samples ofasures of COPD severity.
alue Model R2 Adjusted
b estimatec,a
95% CI P value
.0015 0.078 29 6; 53 0.016
.0001 0.32 13 8; 18 <0.0001
.0001 0.18 1358 2474; 241 0.018
.0016 0.078 3 24; 31 0.80
t variable and each outcome measure as independent variable.
t variable and all 4 outcome measures as independent variables.
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Figure 2 Persons with the same FEV1 % predicted, 6MWT
distance, or SGRQ-TS have a wide range of average daily step
counts.
968 M.L. Moy et al.US persons with COPD is striking. Daily step counts in
healthy older adults has also been shown to be much
greater than those in persons with COPD and what we
observed in our COPD cohort. For examples, healthy older
adults in Seattle, WA walked an average of 11,266 steps per
day compared to 5646 steps per day in COPD,10 and healthy
controls in Belgium walked 9372 steps per day compared to
5115 steps per day in 21 persons with COPD in Pittsburgh,PA.11 Finally, our study is observational, while prospective
and intervention studies are needed to confirm relation-
ships between steps per day and health outcomes.
In conclusion, accurately measured, average daily step
count was 5680 and decreased with increasing GOLD stage
in a cohort of US persons with COPD. Daily step counts
decline over the short-term partly due to season, and
capture information not assessed by current measures of
COPD severity. These findings can aid the design, analysis,
and interpretation of studies of daily step counts in COPD.
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